Reckitt Benckiser Share Price – Live LSE Updates and Analysis

Reckitt Benckiser Group PLC (LSE: RKT) trades at 5,674.00p (buy price) as of the latest London Stock Exchange session, representing a decline of 34.54p or 0.61% from the previous close. The FTSE 100 consumer defensive stock commands a market capitalisation of approximately £36.65 billion, with shares exchanging hands in volume of 2.05 million during the most recent trading day.

The multinomial conglomerate, which maintains primary listing status on the London Stock Exchange under ticker RKT, operates a portfolio of global hygiene and health brands including Lysol, Finish, Durex, and Mucinex. Classified within the consumer defensive sector, the stock typically demonstrates lower correlation with cyclical economic downturns, though recent trading activity shows the security navigating a 52-week range spanning nearly 1,753p between its high and low watermarks.

Current valuation metrics position Reckitt at a price-to-earnings ratio of 32.07, with an indicated dividend yield of 3.5%. The company’s upcoming ex-dividend date falls on 9 April 2026, with a payment of 127.80p per share scheduled for 12 June 2026.

What is the Current Reckitt Benckiser Share Price?

Key Market Insights

• The stock trades with a 10p spread between bid (5,664.00p) and offer (5,674.00p) prices.
• Reckitt maintains FTSE 100 membership within the consumer defensive classification.
• Intraday trading saw a high of 5,720.00p before settling at current levels.
• The ISIN code GB00BSZBP530 identifies the security for settlement purposes.
• Real-time pricing data remains available through the London Stock Exchange and AJ Bell market research platforms.
• Previous session closed at 5,700.00p, establishing the baseline for current percentage calculations.
• The opening auction on the most recent trading day commenced at 5,700.00p.

Live Trading Data Summary

Reckitt Share Price Performance and Historical Trends

Over the past fifty-two weeks, Reckitt shares have oscillated between a peak of 6,522.92p and a trough of 4,769.79p, establishing a volatility band of approximately 27% from peak to trough. This trading range reflects both broader market sentiment toward defensive equities and company-specific developments regarding portfolio restructuring and emerging market exposure.

Relative Performance Benchmarks

On a total-return basis measured to 4 March 2026, Reckitt delivered -1.31% over the trailing twelve-month period, marginally outperforming the FTSE 100 index, which recorded -1.38% over the same timeframe. This near-parity movement suggests the stock maintained its defensive correlation with the broader UK large-cap universe despite individual business catalysts.

Long-Term Historical Context

Historical charting available through AJ Bell’s research platform indicates performance breakdowns across multiple time horizons including 1-day, 1-month, 3-month, 1-year, and annualised 3-year, 5-year, and 10-year intervals. The LSE Analysis page provides downloadable historic data sets for quantitative review.

Reckitt Dividend Yield and Key Financial Metrics

Reckitt currently offers investors a 3.5% dividend yield, supported by cash flows from its portfolio of market-leading brands. The company maintains a schedule of interim and final distributions, with the most recent payment of 87.92p per share processed on 18 September 2025 following an ex-dividend date of 7 August 2025.

Upcoming Distribution Schedule

Shareholders purchasing stock before the ex-dividend date of 9 April 2026 will qualify for the upcoming dividend of 127.80p per share, payable on 12 June 2026 to those on the register as of 10 April 2026. This represents an increase from the previous distribution and corresponds to the company’s stated capital allocation priorities.

Valuation Multiples

The current price-to-earnings ratio of 32.07 places Reckitt at a premium valuation relative to broader UK market averages, reflecting investor willingness to pay elevated multiples for defensive cash flows and global brand equity. This metric, sourced from AJ Bell fundamental data, indicates expectations of sustained earnings generation despite input cost pressures.

Analyst Ratings and Share Price Outlook for Reckitt

Broker coverage aggregated on the London Stock Exchange Analysis portal provides consensus recommendations categorised as Buy, Hold, or Sell, alongside aggregate target price ranges. The specific numerical distribution of ratings and the precise average target price remain subject to real-time updates through the exchange’s dedicated analysis tab.

Earnings Expectations

Analysts monitor quarterly and half-year earnings releases for variance against consensus revenue and operating profit projections. Updates regarding pricing power, volume trends, and input-cost inflation typically catalyse short-term price movements. The LSE company page maintains a financial calendar marking upcoming results announcements, though specific dates require verification through the exchange’s regulatory news service.

Factors Impacting Reckitt Benckiser Share Price

Multiple operational and macroeconomic variables influence daily price discovery for RKT.L. The company’s strategic repositioning toward consumer health and hygiene—evidenced by the 2017 acquisition of Mead Johnson for infant formula entry and subsequent purchases of Schiff Nutrition, K-Y, and Biofreeze—continues reshaping revenue composition and margin profiles.

Geographic Revenue Concentration

Emerging markets contribute over 35% of total sales, exposing the equity to currency fluctuation risks and regional economic volatility. Foreign exchange movements, particularly in Asian and Latin American currencies where Reckitt maintains significant market share, frequently amplify price volatility beyond underlying UK market conditions.

Regulatory and Litigation Exposure

As a manufacturer of health and hygiene products, Reckitt operates under continuous regulatory scrutiny regarding product safety standards. Adverse developments in litigation or regulatory enforcement—common risks within the consumer health sector—can precipitate rapid share price adjustments independent of earnings fundamentals.

Timeline of Recent Reckitt Trading Events

1. 7 August 2025: Ex-dividend date for 87.92p distribution.
2. 18 September 2025: Payment date for interim dividend of 87.92p per share.
3. 10 October 2025: Mead Johnson acquisition anniversary (2017 entry into infant formula).
4. 6 March 2026: Previous trading session closed at 5,580.00p.
5. 9 April 2026: Upcoming ex-dividend date for 127.80p payment.
6. 12 June 2026: Scheduled payment date for forthcoming dividend of 127.80p per share.

Established Facts and Market Uncertainties

Corporate Context and Sector Classification

Reckitt operates within the consumer defensive sector, a classification indicating demand inelasticity for its hygiene and health products during economic contractions. The FTSE 100 membership provides index-tracking mandate support, though the company’s specific risk factors—including MTD for Income Tax considerations for UK shareholders and emerging market operational complexity—differentiate it from domestic-centric defensive plays.

The strategic evolution from a diversified conglomerate to a focused consumer health entity, marked by the divestiture of food operations and acquisition of Mead Johnson, positions the equity as a proxy for global demographic trends in infant nutrition and over-the-counter healthcare rather than purely discretionary consumer spending.

Data Sources and Attribution

“Reckitt Benckiser Group PLC (RKT.L) is a FTSE 100 consumer defensive stock listed on the London Stock Exchange with a market cap of about £36.65bn and a current dividend yield of 3.5%.”

AJ Bell Market Research, LSE:RKT Profile

“RKT is described as having a portfolio of leading global brands such as Lysol, Finish, Durex and Mucinex, many with No.1 or No.2 market positions globally… Significant exposure to emerging markets, which generate over 35% of sales.”

AJ Bell Fundamental Analysis

Summary of Reckitt Investment Position

Reckitt Benckiser trades at 5,674.00p with a £36.65 billion market capitalisation, offering a 3.5% dividend yield supported by upcoming 127.80p distributions. The stock sits mid-range within its 52-week band, having marginally outperformed the FTSE 100 over the trailing year despite a negative absolute return. Investors must weigh the defensive characteristics of its Lysol, Finish, and Durex brands against emerging market currency risks and regulatory exposure inherent in consumer health manufacturing. Those monitoring Alendronic Acid Risks and similar pharmaceutical sector developments should note Reckitt’s distinct positioning in over-the-counter rather than prescription markets, though litigation risks remain a constant consideration for share price stability.

Frequently Asked Questions